Source: Health Products Regulatory Authority (ZA) Publisher: Austell Pharmaceuticals (Pty) Ltd, 1 Sherborne Road, Parktown, JOHANNESBURG, 2193, South Africa, Tel: 0860287835
REZALTO 10 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Pink, round, biconvex film-coated tablets, engraved with “10” on one side, plain on the other. |
Each film-coated tablet contains 10 mg rivaroxaban.
Each film-coated tablet contains 95,6 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated. |
| List of Excipients |
|---|
|
Tablet core: Cellulose, microcrystalline Film-coating: Hypromellose 2910 (E464) |
Tablets are packed in transparent PVC/Aluminium blister strips of 7 or 10, which are further packed in printed cartons, in pack sizes of 10 or 30 tablets.
Not all pack sizes may be marketed.
Austell Pharmaceuticals (Pty) Ltd, 1 Sherborne Road, Parktown, JOHANNESBURG, 2193, South Africa, Tel: 0860287835
REZALTO 10 mg: 53/8.2/0194
03 November 2020
| Drug | Countries | |
|---|---|---|
| REZALTO | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.